ClinicalTrials.Veeva

Menu
C

Clinical Research of West Florida | Tampa, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
Hydrocodone Bitartrate
ABT-494
Tirzepatide
SEL-212
Adalimumab
Neramexane
Naltrexone Hydrochloride
SUN-101
Lubiprostone

Parent organization

This site is a part of Clinical Research of West Florida

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

33 of 111 total trials

24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG

This is a Phase 2, randomized, open-label, 24-week treatment study to evaluate the potential pharmacodynamic (PD) activity, safety, tolerability, and...

Enrolling
Pmm2-CDG
Drug: GLM101

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Upadacitinib
Drug: Upadacitinib

This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and pharmacokinetics (P...

Enrolling
Diabetic Peripheral Neuropathic Pain
Drug: RTA 901
Drug: RTA 901-Matching Placebo

a Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat (an aldosterone synthase inhibitor), administered on a background of a...

Enrolling
Hypertension
Drug: Placebo
Drug: lorundrostat Dose 2

The study objectives of Period 1 are to compare the efficacy, safety, and tolerability of upadacitinib 15 mg once daily (QD) and 30 mg QD versus plac...

Active, not recruiting
Psoriatic Arthritis
Drug: Placebo
Drug: Upadacitinib

This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).

Enrolling
Systemic Lupus Erythematosus
Drug: Placebo
Drug: Obexelimab

The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes a...

Active, not recruiting
Type 2 Diabetes
Drug: Semaglutide
Drug: Orforglipron

The main purpose of this study is to assess the safety and efficacy of peresolimab in adult participants with moderately-to-severely active rheumatoi...

Active, not recruiting
Joint Diseases
Arthritis
Drug: Peresolimab
Drug: Placebo
Recently updated

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of gus...

Active, not recruiting
Crohn's Disease
Drug: Ustekinumab
Drug: Guselkumab Dose 3

The study consists of 4 sub-studies, as follows:* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safet...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Risankizumab IV
Drug: Risankizumab SC

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide
Locations recently updated

This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose fi...

Enrolling
Rheumatoid Arthritis
Drug: SAR441566
Drug: Placebo

This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroi...

Active, not recruiting
Giant Cell Arteritis (GCA)
Drug: Upadacitinib
Other: Placebo

This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab (SAR440340)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

The purpose of this study is to evaluate safety, drug levels and drug effects on cells and organs of the body, after receiving multiple increasing do...

Enrolling
Lupus
Other: Placebo for BMS-986326
Drug: BMS-986326

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). T...

Enrolling
Lupus Erythematosus, Systemic
Drug: Placebo
Drug: Litifilimab

This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (...

Enrolling
Obesity
Drug: Matching Placebo-Garetosmab
Drug: Garetosmab

This is an interventional, Phase III, double-blind, randomized, controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and sa...

Enrolling
Post Surgical Neuropathic Pain
Drug: Qutenza (capsaicin) 8% topical system
Drug: capsaicin 0.04% topical system

Trial sponsors

Lilly logo
AbbVie logo
Boehringer Ingelheim logo
Pfizer logo
Janssen (J&J Innovative Medicine) logo
Purdue Pharma logo
Sanofi logo
Sunovion logo
Viatris logo
B

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems